IN2015DN04175A - - Google Patents

Info

Publication number
IN2015DN04175A
IN2015DN04175A IN4175DEN2015A IN2015DN04175A IN 2015DN04175 A IN2015DN04175 A IN 2015DN04175A IN 4175DEN2015 A IN4175DEN2015 A IN 4175DEN2015A IN 2015DN04175 A IN2015DN04175 A IN 2015DN04175A
Authority
IN
India
Prior art keywords
combination
inhibiting
decreasing
treating
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Qing Sheng
hui qin Wang
Fang Li
Jinsheng Liang
Zhu Alexander Cao
John Monahan
Richard Versace
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN04175A publication Critical patent/IN2015DN04175A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN4175DEN2015 2012-11-07 2013-11-06 IN2015DN04175A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723474P 2012-11-07 2012-11-07
US201361790796P 2013-03-15 2013-03-15
PCT/US2013/068691 WO2014074580A1 (fr) 2012-11-07 2013-11-06 Polythérapie

Publications (1)

Publication Number Publication Date
IN2015DN04175A true IN2015DN04175A (fr) 2015-10-16

Family

ID=49681127

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4175DEN2015 IN2015DN04175A (fr) 2012-11-07 2013-11-06

Country Status (12)

Country Link
US (3) US20150290204A1 (fr)
EP (1) EP2916841A1 (fr)
JP (1) JP2015536986A (fr)
KR (1) KR20150081344A (fr)
CN (1) CN105120868A (fr)
AU (2) AU2013341271A1 (fr)
BR (1) BR112015010396A2 (fr)
CA (1) CA2890699A1 (fr)
IN (1) IN2015DN04175A (fr)
MX (1) MX2015005798A (fr)
RU (1) RU2015121424A (fr)
WO (1) WO2014074580A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201446745A (zh) 2013-02-08 2014-12-16 Celgene Avilomics Res Inc Ｅｒｋ抑制劑及其用途
AU2014372166B2 (en) * 2013-12-23 2017-10-26 Novartis Ag Pharmaceutical combinations
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
WO2016098042A1 (fr) * 2014-12-19 2016-06-23 Novartis Ag Utilisation du céritinib (ldk -378) dans le traitement de troubles médiés par fes ou fer, en particulier des troubles prolifératifs
EP3778605A3 (fr) 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
US11058977B2 (en) 2018-07-23 2021-07-13 Caterpillar Inc. 3D printed staged filtration media packs
US10981335B2 (en) 2019-02-06 2021-04-20 Caterpillar Inc. Filtration media packs produced using additive manufacturing
CN114302878A (zh) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 酪氨酸激酶非受体1(tnk1)抑制剂及其用途
GB201915618D0 (en) * 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
WO2021257857A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés naphtyridinone en tant qu'inhibiteurs de jak2 v617f
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
JO2783B1 (en) 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
JP5208123B2 (ja) 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US8486933B2 (en) * 2009-05-27 2013-07-16 Abbvie Inc. Pyrimidine inhibitors of kinase activity
WO2011060328A1 (fr) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, et procédés pour l'identification, l'évaluation, la prévention, et la thérapie d'un cancer
US20130137709A1 (en) * 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
EA023404B1 (ru) * 2011-02-02 2016-05-31 Новартис Аг Способ лечения немелкоклеточного рака легких
US8906885B2 (en) * 2011-07-07 2014-12-09 Synta Pharmaceuticals Corp. Treating cancer with HSP90 inhibitory compounds

Also Published As

Publication number Publication date
CA2890699A1 (fr) 2014-05-15
KR20150081344A (ko) 2015-07-13
RU2015121424A (ru) 2016-12-27
AU2017200232A1 (en) 2017-02-02
US20160287605A1 (en) 2016-10-06
AU2013341271A1 (en) 2015-05-14
WO2014074580A1 (fr) 2014-05-15
CN105120868A (zh) 2015-12-02
US20150290204A1 (en) 2015-10-15
US20170157134A1 (en) 2017-06-08
BR112015010396A2 (pt) 2017-07-11
JP2015536986A (ja) 2015-12-24
EP2916841A1 (fr) 2015-09-16
MX2015005798A (es) 2015-09-23

Similar Documents

Publication Publication Date Title
IN2015DN04175A (fr)
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
WO2015097621A3 (fr) Combinaisons pharmaceutiques
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
MX369385B (es) Productos para cicatrizar heridas tisulares.
TN2013000414A1 (en) 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
IN2014DN05869A (fr)
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
WO2011151722A3 (fr) Méthodes et compositions de traitement pharmaceutique par voie orale
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
WO2011153458A3 (fr) Compositions et méthodes utilisables en vue de l'inhibition ou du traitement d'une infection par le virus de la dengue
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor